Drugmakers Pfizer, Bayer, Novartis May Join Bidding for Onyx
Inside Wall Street: Interest in Genomic Research Sector Heats Up Again
Big pharma heats up with high performance for drugs, earnings
Animal rights groups step up attacks against Novartis
Winners and losers: Ten headline-making M&A deals
Amgen jumps 15 percent on results of clinical trial
As swine flu becomes a pandemic, where are the vaccines?
Novartis strikes again: New drug shows blockbuster potential
Novartis grabs two growth segments in one deal: Generic and cancer drugs
Pharma Report: New drugs coming, but what about Pfizer?